;PMID: 3773530
;source_file_643.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..197] = [t:47..197]
;2)section:[e:201..236] = [t:201..236]
;3)sentence:[e:240..449] = [t:240..449]
;4)sentence:[e:450..687] = [t:450..687]
;5)sentence:[e:688..792] = [t:688..792]
;6)sentence:[e:793..965] = [t:793..965]
;7)sentence:[e:966..1113] = [t:966..1113]
;8)sentence:[e:1114..1207] = [t:1114..1207]
;9)sentence:[e:1208..1334] = [t:1208..1334]
;10)sentence:[e:1335..1506] = [t:1335..1506]
;11)sentence:[e:1507..1672] = [t:1507..1672]
;12)section:[e:1676..1720] = [t:1676..1720]
;Token/POS Errors
;ERROR_Token in entity file but not tree[97..105] estrogen
;ERROR_Token in entity file but not tree[105..106] -
;ERROR_Token in entity file but not tree[106..107] 2
;ERROR_Token in entity file but not tree[107..108] /
;ERROR_Token in entity file but not tree[108..109] 4
;ERROR_Token in entity file but not tree[109..110] -
;ERROR_Token in entity file but not tree[110..121] hydroxylase
;ERROR_Token in entity file but not tree[275..283] estrogen
;ERROR_Token in entity file but not tree[283..284] -
;ERROR_Token in entity file but not tree[284..285] 2
;ERROR_Token in entity file but not tree[285..286] /
;ERROR_Token in entity file but not tree[286..287] 4
;ERROR_Token in entity file but not tree[287..288] -
;ERROR_Token in entity file but not tree[288..299] hydroxylase
;ERROR_Token in entity file but not tree[539..547] estrogen
;ERROR_Token in entity file but not tree[547..548] -
;ERROR_Token in entity file but not tree[548..549] 2
;ERROR_Token in entity file but not tree[549..550] /
;ERROR_Token in entity file but not tree[550..551] 4
;ERROR_Token in entity file but not tree[551..552] -
;ERROR_Token in entity file but not tree[552..563] hydroxylase
;ERROR_Token in entity file but not tree[1646..1654] estrogen
;ERROR_Token in entity file but not tree[1654..1655] -
;ERROR_Token in entity file but not tree[1655..1656] 2
;ERROR_Token in entity file but not tree[1656..1657] /
;ERROR_Token in entity file but not tree[1657..1658] 4
;ERROR_Token in entity file but not tree[1658..1659] -
;ERROR_Token in entity file but not tree[1659..1671] hydroxylases
;ERROR_Token in tree file but not entity[97..121] estrogen-2/4-hydroxylase
;ERROR_Token in tree file but not entity[275..299] estrogen-2/4-hydroxylase
;ERROR_Token in tree file but not entity[539..563] estrogen-2/4-hydroxylase
;ERROR_Token in tree file but not entity[1646..1671]
;estrogen-2/4-hydroxylases

;section 0 Span:0..41
;J Steroid Biochem. 1986 Oct;25(4):585-91.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Steroid) (NNP:[10..17] Biochem)
        (.:[17..18] .) (CD:[19..23] 1986) (DT:[24..29] Oct;2) (CD:[29..30] 5)
        (-LRB-:[30..31] -LRB-) (NN:[31..32] 4) (-RRB-:[32..33] -RRB-)
        (,:[33..34] :) (CD:[34..36] 58) (CD:[36..40] 5-91) (.:[40..41] .)))

;sentence 1 Span:47..197
;Substrate dependency of specific and non-specific estrogen-2/4-hydroxylase 
;activities measured by the radio-enzymatic method in rat brain microsomes.
;[47..56]:substance:"Substrate"
;[97..107]...[110..121]:substance:"estrogen-2"..."hydroxylase"
;[97..105]...[108..121]:cyp450:"estrogen"..."4-hydroxylase"
(SENT
  (NP-HLN
    (NP (NN:[47..56] Substrate) (NN:[57..67] dependency))
    (PP (IN:[68..70] of)
      (NP
        (NP (JJ:[71..79] specific)
          (NML-2 (-NONE-:[79..79] *P*)))
        (CC:[80..83] and)
        (NP
          (ADJP (AFX:[84..87] non) (HYPH:[87..88] -) (JJ:[88..96] specific))
          (NML-2 (NN:[97..121] estrogen-2/4-hydroxylase)
                 (NNS:[123..133] activities)))))
    (VP (VBN:[134..142] measured)
      (NP (-NONE-:[142..142] *))
      (PP-MNR (IN:[143..145] by)
        (NP (DT:[146..149] the)
          (ADJP (AFX:[150..155] radio) (HYPH:[155..156] -)
                (JJ:[156..165] enzymatic))
          (NN:[166..172] method)))
      (PP-LOC (IN:[173..175] in)
        (NP (NN:[176..179] rat) (NN:[180..185] brain)
            (NNS:[186..196] microsomes))))
    (.:[196..197] .)))

;section 2 Span:201..236
;Theron CN, Russell VA, Taljaard JJ.
(SEC
  (FRAG (NNP:[201..207] Theron) (NNP:[208..210] CN) (,:[210..211] ,)
        (NNP:[212..219] Russell) (NNP:[220..222] VA) (,:[222..223] ,)
        (NNP:[224..232] Taljaard) (NNP:[233..236] JJ.)))

;sentence 3 Span:240..449
;Putative specific and non-specific estrogen-2/4-hydroxylase activities which 
;might affect the radio-enzymatic assay were characterized in terms of their 
;requirements for NADPH and their substrate dependency.
;[275..285]...[288..299]:substance:"estrogen-2"..."hydroxylase"
;[275..283]...[286..299]:cyp450:"estrogen"..."4-hydroxylase"
;[412..417]:substance:"NADPH"
;[428..437]:substance:"substrate"
(SENT
  (S
    (NP-SBJ-4
      (NP (JJ:[240..248] Putative)
        (NML
          (NML (JJ:[249..257] specific)
            (NML-3 (-NONE-:[257..257] *P*)))
          (CC:[258..261] and)
          (NML
            (ADJP (AFX:[262..265] non) (HYPH:[265..266] -)
                  (JJ:[266..274] specific))
            (NML-3 (NN:[275..299] estrogen-2/4-hydroxylase)
                   (NNS:[300..310] activities)))))
      (SBAR
        (WHNP-1 (WDT:[311..316] which))
        (S
          (NP-SBJ-1 (-NONE-:[316..316] *T*))
          (VP (MD:[318..323] might)
            (VP (VB:[324..330] affect)
              (NP (DT:[331..334] the)
                (ADJP (AFX:[335..340] radio) (HYPH:[340..341] -)
                      (JJ:[341..350] enzymatic))
                (NN:[351..356] assay)))))))
    (VP (VBD:[357..361] were)
      (VP (VBN:[362..375] characterized)
        (NP-4 (-NONE-:[375..375] *))
        (PP (IN:[376..378] in)
          (NP
            (NP (NNS:[379..384] terms))
            (PP (IN:[385..387] of)
              (NP
                (NP
                  (NP (PRP$:[388..393] their) (NNS:[395..407] requirements))
                  (PP (IN:[408..411] for)
                    (NP (NN:[412..417] NADPH))))
                (CC:[418..421] and)
                (NP (PRP$:[422..427] their) (NN:[428..437] substrate)
                    (NN:[438..448] dependency))))))))
    (.:[448..449] .)))

;sentence 4 Span:450..687
;Using rat brain  microsomes and partially purified rat liver COMT three main
;sources of  estrogen-2/4-hydroxylase activity could be distinguished; a
;COMT-related  component and NADPH-dependent and NADPH-independent microsomal
;components.
;[511..515]:substance:"COMT"
;[539..549]...[552..563]:substance:"estrogen-2"..."hydroxylase"
;[539..547]...[550..563]:cyp450:"estrogen"..."4-hydroxylase"
;[599..603]:substance:"COMT"
;[627..632]:substance:"NADPH"
;[647..652]:substance:"NADPH"
(SENT
  (S
    (S-ADV
      (NP-SBJ (-NONE-:[450..450] *))
      (VP (VBG:[450..455] Using)
        (NP
          (NP (NN:[456..459] rat) (NN:[460..465] brain)
              (NNS:[467..477] microsomes))
          (CC:[478..481] and)
          (NP
            (ADJP (RB:[482..491] partially) (JJ:[492..500] purified))
            (NN:[501..504] rat) (NN:[505..510] liver) (NN:[511..515] COMT)))))
    (NP-SBJ-2
      (NP
        (NP (CD:[516..521] three) (JJ:[522..526] main) (NNS:[527..534] sources))
        (PP (IN:[535..537] of)
          (NP (NN:[539..563] estrogen-2/4-hydroxylase) (NN:[564..572] activity))))
      (NP-3 (-NONE-:[572..572] *ICH*)))
    (VP (MD:[573..578] could)
      (VP (VB:[579..581] be)
        (VP (VBN:[582..595] distinguished)
          (NP-2 (-NONE-:[595..595] *))
          (::[595..596] ;)
          (NP-3
            (NP (DT:[597..598] a)
              (ADJP (NN:[599..603] COMT) (HYPH:[603..604] -)
                    (VBN:[604..611] related))
              (NN:[613..622] component))
            (CC:[623..626] and)
            (NP
              (NP
                (ADJP (NN:[627..632] NADPH) (HYPH:[632..633] -)
                      (JJ:[633..642] dependent))
                (NML-1 (-NONE-:[642..642] *P*)))
              (CC:[643..646] and)
              (NP
                (ADJP (NN:[647..652] NADPH) (HYPH:[652..653] -)
                      (JJ:[653..664] independent))
                (NML-1 (JJ:[665..675] microsomal) (NNS:[676..686] components))))))))
    (.:[686..687] .)))

;sentence 5 Span:688..792
;The  COMT-related activity required NADPH and showed about equal preferences
;for  estrone and estradiol.
;[693..697]:substance:"COMT"
;[724..729]:substance:"NADPH"
;[770..777]:substance:"estrone"
;[782..791]:substance:"estradiol"
(SENT
  (S
    (NP-SBJ (DT:[688..691] The)
      (ADJP (NN:[693..697] COMT) (HYPH:[697..698] -) (VBN:[698..705] related))
      (NN:[706..714] activity))
    (VP
      (VP (VBD:[715..723] required)
        (NP (NN:[724..729] NADPH)))
      (CC:[730..733] and)
      (VP (VBD:[734..740] showed)
        (NP
          (QP (RB:[741..746] about) (JJ:[747..752] equal))
          (NNS:[753..764] preferences))
        (PP (IN:[765..768] for)
          (NP (NN:[770..777] estrone) (CC:[778..781] and)
              (NN:[782..791] estradiol)))))
    (.:[791..792] .)))

;sentence 6 Span:793..965
;The NADPH-dependent component was highly specific for  estradiol, the
;relative activities observed with estrone and estriol being 7 and  1% of that
;observed with estradiol.
;[797..802]:substance:"NADPH"
;[848..857]:substance:"estradiol"
;[897..904]:substance:"estrone"
;[909..916]:substance:"estriol"
;[923..924]...[931..932]:quantitative-value:"7"..."%"
;[930..932]:quantitative-value:"1%"
;[955..964]:substance:"estradiol"
(SENT
  (S
    (NP-SBJ (DT:[793..796] The)
      (ADJP (NN:[797..802] NADPH) (HYPH:[802..803] -) (JJ:[803..812] dependent))
      (NN:[813..822] component))
    (VP (VBD:[823..826] was)
      (ADJP-PRD (RB:[827..833] highly) (JJ:[834..842] specific)
        (PP (IN:[843..846] for)
          (NP (NN:[848..857] estradiol))))
      (,:[857..858] ,)
      (S-ADV
        (NP-SBJ
          (NP (DT:[859..862] the) (JJ:[863..871] relative)
              (NNS:[872..882] activities))
          (VP (VBN:[883..891] observed)
            (NP (-NONE-:[891..891] *))
            (PP (IN:[892..896] with)
              (NP (NN:[897..904] estrone) (CC:[905..908] and)
                  (NN:[909..916] estriol)))))
        (VP (VBG:[917..922] being)
          (NP-PRD
            (NP
              (NP (CD:[923..924] 7)
                (NML-1 (-NONE-:[924..924] *P*)))
              (CC:[925..928] and)
              (NP (CD:[930..931] 1)
                (NML-1 (NN:[931..932] %))))
            (PP (IN:[933..935] of)
              (NP
                (NP (DT:[936..940] that))
                (VP (VBN:[941..949] observed)
                  (NP (-NONE-:[949..949] *))
                  (PP (IN:[950..954] with)
                    (NP (NN:[955..964] estradiol))))))))))
    (.:[964..965] .)))

;sentence 7 Span:966..1113
;The NADPH-independent component exhibited  substrate saturation, was
;heat-labile and could not be inhibited by  alpha-naphthoflavone or
;metyrapone.
;[970..975]:substance:"NADPH"
;[1009..1018]:substance:"substrate"
;[1078..1098]:substance:"alpha-naphthoflavone"
;[1102..1112]:substance:"metyrapone"
(SENT
  (S
    (NP-SBJ-1 (DT:[966..969] The)
      (ADJP (NN:[970..975] NADPH) (HYPH:[975..976] -)
            (JJ:[976..987] independent))
      (NN:[988..997] component))
    (VP
      (VP (VBD:[998..1007] exhibited)
        (NP (NN:[1009..1018] substrate) (NN:[1019..1029] saturation)))
      (,:[1029..1030] ,)
      (VP (VBD:[1031..1034] was)
        (ADJP-PRD (NN:[1035..1039] heat) (HYPH:[1039..1040] -)
                  (JJ:[1040..1046] labile)))
      (CC:[1047..1050] and)
      (VP (MD:[1051..1056] could) (RB:[1057..1060] not)
        (VP (VB:[1061..1063] be)
          (VP (VBN:[1064..1073] inhibited)
            (NP-1 (-NONE-:[1073..1073] *))
            (PP (IN:[1074..1076] by)
              (NP-LGS (NN:[1078..1098] alpha-naphthoflavone)
                      (CC:[1099..1101] or) (NN:[1102..1112] metyrapone)))))))
    (.:[1112..1113] .)))

;sentence 8 Span:1114..1207
;It showed a preference for estrone over  estradiol, with estriol being a very
;poor substrate.
;[1141..1148]:substance:"estrone"
;[1155..1164]:substance:"estradiol"
;[1171..1178]:substance:"estriol"
;[1197..1206]:substance:"substrate"
(SENT
  (S
    (NP-SBJ (PRP:[1114..1116] It))
    (VP (VBD:[1117..1123] showed)
      (NP
        (NP (DT:[1124..1125] a) (NN:[1126..1136] preference))
        (PP (IN:[1137..1140] for)
          (NP (NN:[1141..1148] estrone)))
        (PP (IN:[1149..1153] over)
          (NP (NN:[1155..1164] estradiol))))
      (,:[1164..1165] ,)
      (PP (IN:[1166..1170] with)
        (S-NOM
          (NP-SBJ (NN:[1171..1178] estriol))
          (VP (VBG:[1179..1184] being)
            (NP-PRD (DT:[1185..1186] a)
              (ADJP (RB:[1187..1191] very) (JJ:[1192..1196] poor))
              (NN:[1197..1206] substrate))))))
    (.:[1206..1207] .)))

;sentence 9 Span:1208..1334
;These findings indicate  that non-enzymatic factors contribute very little to
;product formation in the  radio-enzymatic assay.
;[1286..1293]:substance:"product"
(SENT
  (S
    (NP-SBJ (DT:[1208..1213] These) (NNS:[1214..1222] findings))
    (VP (VBP:[1223..1231] indicate)
      (SBAR (IN:[1233..1237] that)
        (S
          (NP-SBJ
            (ADJP (AFX:[1238..1241] non) (HYPH:[1241..1242] -)
                  (JJ:[1242..1251] enzymatic))
            (NNS:[1252..1259] factors))
          (VP (VBP:[1260..1270] contribute)
            (NP (RB:[1271..1275] very) (JJ:[1276..1282] little))
            (PP-CLR (TO:[1283..1285] to)
              (NP (NN:[1286..1293] product) (NN:[1294..1303] formation)))
            (PP (IN:[1304..1306] in)
              (NP (DT:[1307..1310] the)
                (ADJP (AFX:[1312..1317] radio) (HYPH:[1317..1318] -)
                      (JJ:[1318..1327] enzymatic))
                (NN:[1328..1333] assay)))))))
    (.:[1333..1334] .)))

;sentence 10 Span:1335..1506
;The specificity of the major NADPH-dependent microsomal  component towards
;estradiol suggests a stereo-specific requirement for the  D-ring
;configuration of this estrogen.
;[1364..1369]:substance:"NADPH"
;[1410..1419]:substance:"estradiol"
;[1497..1505]:substance:"estrogen"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1335..1338] The) (NN:[1339..1350] specificity))
      (PP (IN:[1351..1353] of)
        (NP (DT:[1354..1357] the) (JJ:[1358..1363] major)
          (ADJP (NN:[1364..1369] NADPH) (HYPH:[1369..1370] -)
                (JJ:[1370..1379] dependent))
          (JJ:[1380..1390] microsomal) (NN:[1392..1401] component)))
      (PP (IN:[1402..1409] towards)
        (NP (NN:[1410..1419] estradiol))))
    (VP (VBZ:[1420..1428] suggests)
      (NP
        (NP (DT:[1429..1430] a)
          (ADJP (AFX:[1431..1437] stereo) (HYPH:[1437..1438] -)
                (JJ:[1438..1446] specific))
          (NN:[1447..1458] requirement))
        (PP (IN:[1459..1462] for)
          (NP
            (NP (DT:[1463..1466] the) (NN:[1468..1474] D-ring)
                (NN:[1475..1488] configuration))
            (PP (IN:[1489..1491] of)
              (NP (DT:[1492..1496] this) (NN:[1497..1505] estrogen)))))))
    (.:[1505..1506] .)))

;sentence 11 Span:1507..1672
;The use of no-cofactor blanks in the  radio-enzymatic assay may be very
;important when different estrogens are  compared as substrates for
;estrogen-2/4-hydroxylases.
;[1604..1613]:substance:"estrogens"
;[1631..1641]:substance:"substrates"
;[1646..1656]...[1659..1671]:substance:"estrogen-2"..."hydroxylases"
;[1646..1654]...[1657..1671]:cyp450:"estrogen"..."4-hydroxylases"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1507..1510] The) (NN:[1511..1514] use))
      (PP (IN:[1515..1517] of)
        (NP
          (NML (DT:[1518..1520] no) (HYPH:[1520..1521] -)
               (NN:[1521..1529] cofactor))
          (NNS:[1530..1536] blanks)))
      (PP-LOC (IN:[1537..1539] in)
        (NP (DT:[1540..1543] the)
          (ADJP (AFX:[1545..1550] radio) (HYPH:[1550..1551] -)
                (JJ:[1551..1560] enzymatic))
          (NN:[1561..1566] assay))))
    (VP (MD:[1567..1570] may)
      (VP (VB:[1571..1573] be)
        (ADJP-PRD (RB:[1574..1578] very) (JJ:[1579..1588] important))
        (SBAR-TMP (WRB:[1589..1593] when)
          (S
            (NP-SBJ-1 (JJ:[1594..1603] different) (NNS:[1604..1613] estrogens))
            (VP (VBP:[1614..1617] are)
              (VP (VBN:[1619..1627] compared)
                (NP-1 (-NONE-:[1627..1627] *))
                (PP (IN:[1628..1630] as)
                  (NP
                    (NP (NNS:[1631..1641] substrates))
                    (PP (IN:[1642..1645] for)
                      (NP (NNS:[1646..1671] estrogen-2/4-hydroxylases)))))))))))
    (.:[1671..1672] .)))

;section 12 Span:1676..1720
;PMID: 3773530 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1676..1680] PMID) (::[1680..1681] :) (CD:[1682..1689] 3773530)
        (NN:[1690..1691] -LSB-) (NNP:[1691..1697] PubMed) (::[1698..1699] -)
        (NN:[1700..1707] indexed) (IN:[1708..1711] for)
        (NNP:[1712..1720] MEDLINE-RSB-)))
